Feature | Breast Imaging | March 07, 2018 | By Jeff Zagoudis

Greater Evidence, Payment Expansion Driving Tomosynthesis Adoption

This article originally ran as the Breast Tomosynthesis Systems chart introduction in the March 2018 issue. The chart can be viewed here.

Fujifilm introduced a DBT option to the Aspire Cristalle full-field digital mammography (FFDM) system in 2017 following FDA approval for the upgrade.

Fujifilm introduced a DBT option to the Aspire Cristalle full-field digital mammography (FFDM) system in 2017 following FDA approval for the upgrade.

In the world of breast imaging, digital breast tomosynthesis (DBT) is a relative newcomer, only being adopted into clinical practice in the last 8 years. The benefits of DBT, also known as 3-D mammography, are generally understood — improved cancer detection over traditional 2-D mammography due to the ability to scroll through different slices of the breast to see lesions undetectable in two dimensions. While the evidence for DBT has been mounting, new data reveal the technology has seen explosive growth in the last 18 months.

The U.S. Food and Drug Administration (FDA) tracks statistics on certified mammography facilities and systems across the United States under the directive of the Mammography Quality Standards Act (MQSA), and in June 2016 the FDA began monitoring certification of breast tomosynthesis systems. At that time, out of 8,740 mammography facilities in the U.S., just 2,444 (about 28 percent) had 3-D mammography systems (for a total of 3,362 DBT machines). As of Dec. 1 of last year, however, FDA data showed a total of 5,394 systems in service at 3,866 centers.

“There is still plenty of lingering confusion caused by screening guidelines that were developed with 2-D technology in mind, which is having a negative impact on the adoption of tomosynthesis in some areas,” said Tracy Accardi, global vice president of research and development, breast and skeletal health division at Hologic. Accardi attributed the rapid growth of DBT to expanding clinical evidence, as well as several recent state and national payer updates that she said have brought the total population of women ages 40 to 75 covered for tomosynthesis to 90 percent.

 

Tomo Vendors Remain Limited

Currently, Hologic is one of only four DBT manufacturers in the market, joined by Siemens, Fujifilm and GE Healthcare.

Hologic was the first to bring tomosynthesis to the commercial market when it received FDA approval for the Selenia Dimensions system in 2011. Its newest premium DBT system, 3Dimensions, provides high-quality 3-D images with Clarity HD High-Resolution 3-D imaging to clearly reveal subtle lesions and fine calcifications, regardless of a patient’s breast size or fibroglandular breast density. The 3Dimensions system also features Intelligent 2-D mapping technology that allows radiologists to instantly move from suspicious areas on the 2-D results to the point of interest on the 3-D slice, optimizing workflow. Clarity HD High-Resolution 3-D imaging and Intelligent 2-D technology are both pending FDA approval.

Siemens Healthineers made the most recent introduction to the market, debuting its newest premium digital mammography system, Mammomat Revelation, at the 2017 Radiological Society of North America (RSNA) annual meeting last November in Chicago. The Mammomat Revelation features 50-degree 3-D HD Breast Tomosynthesis, which Siemens says is the widest scan angle in the industry. In addition, the system adds an HD Breast Biopsy feature that allows the acquisition and scanning of biopsy samples at a single station (rather than two separate systems as is custom) in 20 seconds or less, significantly streamlining workflow. Technologists can target a suspicious area in a scan with one click, down to ±1 mm accuracy. The Mammomat Revelation is still pending FDA approval.

Fujifilm introduced a DBT option to the Aspire Cristalle full-field digital mammography (FFDM) system in 2017 following FDA approval for the upgrade. Unlike other mammography systems, the detector on the Aspire Cristalle uses a hexagonal close pattern (HCP) design, which Fujifilm says improves the efficiency of signal capture and results in a higher-quality image. The system also features advanced image processing and image acquisition workflow to optimize patient dose.

GE Healthcare put the emphasis on patient comfort with its latest mammography system release, the Senographe Pristina, which debuted at RSNA 2016 and was cleared by the FDA in September last year. The system takes what is often the most uncomfortable part of the mammography exam for patients — breast compression — and literally puts it in the patient’s hands with the Dueta remote control. The patient can gradually increase compression after initial setup from the technologist until adequate compression is achieved.

Hologic also brought the idea of patient-centered care to the new 3Dimensions system via the SmartCurve breast stabilization system (which is still pending FDA approval). This compression plate features a curved surface that mirrors the shape of a woman’s breast to reduce pinching and allow better distribution of force over the entire breast. 

Related Content

VolparaEnterprise data analysis shows mammography screening volumes are quickly increasing
News | Mammography | June 09, 2020
June 9, 2020 — More than 75 percent of hospitals and imaging centers that perform mammography across the United State
Developed by medical AI company Lunit, Software detects breast cancer with 97% accuracy; Study in Lancet Digital Health shows that Lunit INSIGHT MMG-aided radiologists showed an increase in sensitivity

Lunit INSIGHT MMG

News | Artificial Intelligence | June 02, 2020
June 2, 2020 — Lunit announced that its artificia...
AI has the potential to help radiologists improve the efficiency and effectiveness of breast cancer imaging

Getty Images

Feature | Breast Imaging | May 28, 2020 | By January Lopez, M.D.
Headlines around the world the past several months declared that...
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

News | Breast Imaging | May 26, 2020
May 26, 2020 — Breast cancer is the most common cancer in women.
Phone call and linkage-to-care-based intervention increases mammography uptake among primary care patients at an urban safety-net hospital

Getty Images

News | Mammography | May 22, 2020
May 22, 2020 — Telephone outreach coupled with scheduling assistance significantly increased...
The Breast Imaging and Reporting System (BI-RADS) was established by the American College of Radiology to help classify findings on mammography. Findings are classified based on the risk of breast cancer, with a BI-RADS 2 lesion being benign, or not cancerous, and BI-RADS 6 representing a lesion that is biopsy-proven to be malignant.

Getty Images

News | Breast Imaging | May 19, 2020
May 19, 2020 — Women with mammographically detected breast lesions that are probably benign should have follow-up sur
Podcast: Impact of COVID-19 on Breast Cancer Treatment with Dr. Andrea Madrigrano

Kubtec hosts a Podcast: Impact of COVID-19 on Breast Cancer Treatment with Andrea Madrigrano, M.D., as part of its public service campaign.

News | Coronavirus (COVID-19) | May 06, 2020
May 6, 2020 — The COVID-19 pandemic is an unprec
The American Society of Breast Surgeons (ASBrS), the National Accreditation Program for Breast Centers (NAPBC), the National Comprehensive Cancer Network (NCCN), the Commission on Cancer (CoC) of the American College of Surgeons, and the American College of Radiology (ACR) have released new joint recommendations for prioritization, treatment and triage of breast cancer patients during the coronavirus (COVID-19) pandemic

Getty Images

News | Breast Imaging | April 13, 2020
April 13, 2020 — The American Society of Breast Surgeons (...